program in September 2006 at 2, 4, and 12-13 months of age, alongside a 12-month catch-up campaign for all children aged ≤2 years [4] .
This program, with reported infant vaccination coverage of >90% by 12 months of age [5] , resulted in a 34% overall reduction in IPD by [2009] [2010] , through a combination of direct and indirect benefits (herd protection), with greatest decline in <2-year-olds (56%) followed by 2-to 4-year-olds (43%) [6] . In April 2010, PCV7 was replaced with a 13-valent vaccine (PCV13), providing additional protection against 6 other serotypes (1, 3, 5, 6A, 7F, and 19A) [7] .
IPD in neonates and young infants is uncommon but well recognized [8] [9] [10] [11] . In the United States, where the prevaccine IPD incidence in <90-day-olds was 11.8 (95% confidence interval [CI], 9.6-14.5) per 100 000 live births, a significant reduction in PCV7 IPD as well as overall IPD incidence was observed within 3 years of PCV7 introduction, even though most infants in this age group would have been too young to receive any direct protection from vaccination [12] .
In England and Wales, the epidemiology of IPD in infants aged <90 days and any impact due to the national PCV7 program have not been documented. Given the differences in schedule and indirect protection effects observed between the United States and the United Kingdom [4] , it is important to evaluate the impact of PCV7 on IPD in young infants in the UK setting. This study therefore aimed to estimate the incidence of IPD, serotype distribution, and impact of PCV7 on PCV7 IPD and IPD caused by other serotypes in infants aged <90 days and to describe risk factors, clinical features, and outcome during the 4 years after PCV7 introduction.
METHODS

IPD Surveillance
The Health Protection Agency (HPA) has been conducting IPD surveillance in England and Wales since the mid-1990s [3] , and the surveillance methodology has been described recently [6] . In brief, the HPA routinely collects computerized hospital laboratory reports of IPD episodes and encourages National Health Service (NHS) hospital microbiologists to submit pneumococcal isolates for confirmation and serotyping to the HPA [6] . From January 2006, polymerase chain reaction (PCR) confirmation was also offered by the HPA on cerebrospinal and pleural fluid samples from patients with suspected meningitis or empyema, respectively, with serotyping performed by a nonculture microsphere-based pneumococcal polysaccharide antigen assay that detects 14 serotypes [13] . Antimicrobial susceptibility testing was performed according to British Society for Antimicrobial Chemotherapy guidelines in local hospital microbiology laboratories, but only some laboratories routinely reported results electronically to the HPA [14] .
This study reports on laboratory-confirmed IPD cases in infants aged <90 days in England and Wales during July 1998-June 2010. IPD was defined as identification of S. pneumoniae through culture from a normally sterile site or dual-target PCR in cerebrospinal or pleural fluid. Meningitis was defined as S. pneumoniae identified in cerebrospinal fluid or clinical and/or radiologic features of meningitis with S. pneumoniae identification in the blood. Death attributable to IPD was defined as S. pneumoniae identification in a normally sterile site with clinical, radiological, and/or histopathological evidence of invasive bacterial infection and appropriate exclusion of other differential diagnoses.
Clinical Data Collection After PCV7 Introduction
Clinical information, including known risk factors for IPD [15] , for laboratory-confirmed IPD cases after PCV7 introduction was obtained by requesting the child's general practitioner and/or pediatrician to complete a questionnaire. Missing information and unreturned questionnaires were followed up by telephone. Fatal cases were followed up by requesting a hospital discharge summary and, if performed, a postmortem report.
Data Analysis
Data were entered into Microsoft Access and analyzed using Stata version 12.0 (StataCorp). Annual IPD incidence was calculated by epidemiological year using Office of National Statistics midyear population estimates as the denominator (www.statistics.gov.uk). The binomial method was used to calculate 95% CIs. PCV7 impact on IPD incidence was estimated as described previously [6] . Because the age distribution, sex, clinical presentation, comorbidity prevalence, and outcome of IPD in infants with known pneumococcal serotype was similar to IPD in infants with no serotype information (data not shown), changes in proportion of serotyped pneumococcal isolates causing IPD annually were adjusted with the assumption that cases with missing serotype data had the same serotype distribution as cases with known serotype (Table 1) .
Prior to PCV7 introduction, an increasing trend in IPD case ascertainment was observed across all age groups [6] , including <90-day-olds. At the same time, a parallel increase in other invasive bacterial infections reported to HPA was noted, which continued up until 2009-2010 [16] . To correct for this increase, the average percentage annual change in total IPD from 1998-1999 to 2005-2006 (calculated to be 4.2% in <90-day-olds) was used to retrospectively increase counts to the only culture-confirmed cases (accounting for >95% of IPD in this age group) were used to assess trends. For clinical data, continuous variables that did not follow a normal distribution are described as median and interquartile range (IQR) and compared using the Mann-Whitney U test. Proportions were compared using the χ 2 test or Fisher exact test, as appropriate. IPD incidence by gestation was calculated by applying the gestational stratification of births in England [17] to the total England and Wales population and adjusting for the 43-month surveillance period. Multivariable logistic regression was used to calculate the adjusted odds ratio (AOR) and 95% CI for clinical presentation with meningitis and increasing age in months after adjusting for sex, comorbidities, prematurity status, vaccination, and year of infection. Multivariable logistic regression was also used to evaluate risk factors associated with death; explanatory variables included age in days and time in days since PCV7 introduction as continuous variables and sex, vaccination status, infecting serotype group, comorbidities, and specific clinical presentations as categorical variables.
Ethical Approval
The HPA has approval under Patient Information Advisory Group Section 60 of the Health and Social Care Act 2001 to process confidential patient information for public health purposes.
RESULTS
Epidemiology
During the period 1998-1999 through 2005-2006, there were 480 culture-confirmed IPD cases in infants aged <90 days in England and Wales, accounting for 1.1% (480/42 875) of all cases and 9.2% (480/5219) of cases in <5-year-olds. The estimated annual incidence during this period was 13.0 (95% CI, 12.0-14.0) per 100 000 live births ( Figure 1 ) and PCV7 serotypes were responsible for 44% of serotyped isolates (Table 1) . Serotypes included in the 10-valent (1, 5, and 7F) and 13-valent (additional 3, 6A, and 19A) pneumococcal conjugate vaccines accounted for 49% and 62% of serotyped isolates, respectively. Among non-PCV7 IPD cases, 4 serotypes (1, 3, 7F, and 8) accounted for more than half of the serotyped isolates (Table 1) .
PCV7 IPD incidence fell rapidly after PCV7 introduction in September 2006 (Figure 1 ), such that there were only 6 PCV7 IPD cases in 2009-2010. There was also a nonsignificant declining trend in overall IPD incidence without any noticeable increase in non-PCV7 IPD ( Table 2 ). The decline in PCV7 IPD was less marked in the first week of life ( Figure 2 ). In 2009-2010, the additional 6 PCV13 serotypes accounted for 62% of serotyped cases. 
Clinical Features of IPD Cases After PCV7 Introduction
Between 4 September 2006 and 30 June 2010, the HPA received reports of 265 potential IPD cases in <90-day-olds. Of these, 9 fatal cases with pneumococcal isolates from sterile sites taken at postmortem were excluded, including 2 intrauterine deaths following maternal IPD resulting in chorioamnionitis at 19 weeks' gestation and at term. In an additional 7 cases who died in the second (n = 3) or third month (n = 4) of life, S. pneumoniae was isolated from postmortem lung swabs with no histopathological evidence of respiratory tract infection and were subsequently registered to have died of sudden unexpected death in infancy. The remaining 256 infants all had a single episode of laboratory-confirmed IPD, which was confirmed by either culture (n = 251, 98.0%) or PCR (n = 5, 2.0%). Ethnicity was reported in 121 and included 91 (75%) white, 11 (9%) from the Indian subcontinent, 7 (6%) black Afro-Caribbean, and 12 (10%) other ethnicities. Of the 131 (51.2%) infants developing IPD in the neonatal (<30 days) period, 101 (39.5%) presented within 7 days and 84 (32.8%) within 48 hours of birth, with no secondary peak in cases. The contribution of PCV7 IPD was similar in the different age groups (Table 3) . Two of 61 infants (3.3%) aged 30-59 days and 41 of 63 (65.1%) aged 60-89 days had received a PCV7 dose prior to IPD. Almost a quarter (60/256, 23.4%) had been born prematurely (median gestational age, 34 [IQR, 32-36] weeks). Compared with term infants (n = 196; 8.4 per 100 000 live births without adjustment for trends in case ascertainment), preterm infants (n = 60; 29.7 per 100 000) had a 3.4-fold (95% CI, 2.5-4.5; P < .0001) higher IPD incidence. IPD rates in infants born at 32-36 (n = 47), 28-31 (n = 10), and <28 (n = 3) weeks' gestation were 33.2 (95% CI, 24.4-44.2), 30.9 (14.9-57.0), and 10.7 (2.2-31.4) cases per 100 000 live births, respectively. Those developing IPD in the first 2 days of life were more likely to be premature compared with those developing IPD on days 3-89 (35/84 [41.7%] vs 25/172 [14.5%], P < .0001). Twelve (4.7%) infants (7 of whom were also premature) had comorbidities, including congenital heart disease (5 cases), multiple congenital abnormalities (2 cases), immunosuppression (2 cases), chronic lung disease of prematurity (2 cases), and acute renal failure (1 case).
Clinical presentations between premature and term infants were similar and meningitis increased with age (AOR, 1.92 [95% CI, 1.44-2.58] per month of life after adjusting for sex, comorbidities, prematurity status, vaccination, and year of infection; P < .0001; Table 3 ). Over the 4 years after PCV7 introduction, comorbidity prevalence, prematurity status, and outcome did not change significantly.
Case Fatality After PCV7 Introduction
Eighteen infants (7.0%) died; 11 in intensive care, 1 in the pediatric ward, and 1 on the way to hospital. The remaining 5 were found dead at home and subsequently diagnosed with IPD postmortem. There was no association between case fatality and age at IPD, prematurity, comorbidity, or serotype group (P > .10), although the number of deaths in these each of different groups was small. Among serotyped cases, PCV7 IPD deaths were caused by serotypes 18C (n = 2), 14 (n = 1), and 19F (n = 1) while non-PCV7 IPD deaths were caused by serotypes 1 (n = 3), 3 (n = 3), and 19A (n = 1). In a logistic regression model, only clinical presentation with meningitis (OR 3.8 [95% CI, 1.2-12.0], P = .024) was significantly associated with death.
Antibiotic Sensitivity of IPD Isolates After PCV7 Introduction
Penicillin sensitivity was reported for 93 isolates and only 1 (1.1%) was resistant and 1 (1.1%) was intermediate resistant.
The penicillin-resistant isolate caused nonfatal septicemia in a 2-month-old infant born at 29 weeks' gestation who subsequently developed chronic lung disease. The isolate with intermediate penicillin resistance caused congenital pneumonia in an otherwise healthy newborn at 35 weeks' gestation who survived. Erythromycin sensitivity was reported for 68 isolates and only 1 (1.5%) isolate from a term newborn with septicemia who survived was resistant.
DISCUSSION
Prior to routine pneumococcal vaccination, IPD incidence in infants aged <90 days in England and Wales was 13.0 per 100 000 live births, and PCV7 serotypes contributed to 44% of cases. The introduction of PCV7 resulted in rapid and significant reduction in PCV7 IPD in young infants, most of whom Figure 2 . Proportion of invasive pneumococcal disease cases in infants aged <90 days that was due to serotypes covered by the 7-valent pneumococcal conjugate vaccine serotypes by age group and epidemiological year. Abbreviations: IPD, invasive pneumococcal disease; PCV7, 7-valent pneumococcal conjugate vaccine.
would have been too young to have directly benefited from pneumococcal vaccination. Almost 40% of cases occurred in the first week of life, where almost 40% were premature and >80% developed septicemia. Meningitis occurred in approximately 40% of infants, increased with age, and was associated with higher case fatality.
In the United States, IPD incidence in <2-year-olds prior to PCV7 introduction was reported to be much higher (160-180 per 100 000 children) than the United Kingdom (35.7 per 100 000) [3] or Western Europe overall (20-35 per 100 000) [18] . Possible explanations for the higher US incidence include a higher proportion of at-risk populations (eg, Alaska Native, American Indian, black populations) and lower threshold for performing blood cultures in febrile children, especially in an outpatient setting, which would increase detection of occult bacteremia [6, 18] . In <90-day-olds, however, our estimated incidence is comparable to the US population-based study (11.8 per 100 000 live births) [12] , perhaps because young infants are more likely to develop severe IPD, be hospitalized and have lower thresholds for having blood cultures taken in both settings.
In the US study, where infants are routinely immunized at 2, 4, 6, and 12-15 months, PCV7 serotypes initially accounted for 71% of IPD in young infants. PCV7 introduction in 2000 resulted in a 39% (P < .001) overall and 67% (P = .004) PCV7 IPD reduction within 3 years [12] compared with reductions of 25% and 83%, respectively, in our cohort, where prevaccine PCV7 IPD prevalence was 44%. Notably, the United States also had a higher proportion of black-African infants (34% vs 6%) who have a much higher risk of IPD [12] . Indeed, the reduction in infant IPD in the United States occurred primarily among black Africans (from 17.1 to 5.2 per 100 000 live births, P = .001) with a lower impact among white infants (from 9.6 to 6.8 per 100 000 live births, P = .11) [12] .
When compared with group B streptococcus (GBS), one of the most common pathogens in young infants, IPD incidence was 7-fold lower (9.8 vs 72 per 100 000 live births), but with a higher proportion developing meningitis (36.7% vs 21.5%) and comparable case fatality (7.0% vs 9.7%) [19] . Like other neonatal pathogens causing early-onset sepsis, S. pneumoniae is often acquired from the maternal genital tract during childbirth [10, 20, 21] . It is interesting to note that, in England and Wales, the contribution of PCV7 serotypes to IPD in young infants prior to PCV7 introduction (44%) was similar to that of 15-to 44-year-olds (733/1850, 40%) than <2-year-olds (558/741, 75%) or 2-to 4-year-olds (238/329, 72%) [6] .
The reduction in PCV7 IPD achieved through indirect protection in young infants starting from birth suggests complex interactions between infants, siblings, parents, and other household contacts. It is likely that, by reducing carriage, PCV7 has reduced transmission of vaccine serotypes from vaccinated siblings to other household contacts. A pre-PCV7 US study, for example, found that neonates with IPD were more likely to be infected with a PCV7 serotype if there were at least 2 siblings in the household and/or if siblings attended childcare [20] . In our cohort, the reduction in proportion of PCV7 IPD cases was more rapid in 2-month-olds (Figure 2) , suggesting some protection offered by a single dose of PCV7 [22] . This is in keeping with our vaccine effectiveness estimates of 56% in infants receiving 1 PCV7 dose before 12 months of age [22] . In the first week of life, though, the decline in PCV7-IPD was less marked, perhaps because the pathogen was most likely acquired from the mother. In contrast to other neonatal pathogens such as GBS, S. pneumoniae rarely (<1%) colonizes the female genital tract [23, 24] and has a much higher infant invasion to maternal colonization ratio, prompting many clinicians to propose empiric antibiotic treatment for pregnant women or neonates colonized with S. pneumoniae [20, 21, 25] . Although IPD risk does not appear to be increased during pregnancy [26] , infection in late pregnancy can lead to fetal infection in utero and premature delivery with all its complications, including death [9, 10, 20, 27] . The high prevalence of prematurity among infants diagnosed at (or soon after) birth, for example, suggests that pneumococcal infection may have occurred in utero and could have contributed to premature birth. Moreover, 2 nonviable fetuses following maternal infection during pregnancy were diagnosed with IPD at postmortem.
The provision of a free national reference service for pneumococcal serotyping and combination of multiple data sources to enhance national surveillance ensures high case ascertainment. Moreover, uniform surveillance methodology allowed us to detect increasing pre-PCV7 IPD trends and adjust for them after PCV7 introduction. In our analysis, we assumed that the serotype distribution among nonserotyped isolates was similar to serotyped isolates on the basis that local hospital laboratories submitted clinical isolates to the national reference center without prior knowledge of the serotype, hence negating any bias between PCV7 and non-PCV7 isolates. This assertion is supported by comparable age distribution, clinical presentation, and outcome of IPD between cases with known serotype and those with unknown serotype. Isolates were usually not serotyped because laboratories reporting the infection electronically may not have submitted the isolate for serotyping or because the isolate failed to grow at the reference laboratory.
Our estimates for IPD incidence in this age group, however, must be considered a minimum for a number of reasons. Blood cultures of infants with suspected early-onset sepsis whose mothers received intrapartum antibiotics, for example, would most likely be negative and, therefore, not picked up by our surveillance. Stillbirths and septic abortion due to IPD may also be missed if a thorough postmortem examination is not performed soon after birth. Finally, PCR testing was introduced nationally only in 2006 and is currently restricted to cerebrospinal and pleural fluid. Increasing use of this service may improve IPD confirmation in milder, culture-negative cases and in patients who received antibiotics prior to taking cultures.
Thus, PCV7 introduction has resulted in a significant reduction in PCV7 IPD and a reduction in overall IPD in young infants. The replacement of PCV7 with PCV13 in April 2010 is likely to reduce IPD incidence further [28] , given that the 6 additional serotypes were responsible for 62% of IPD cases in this age group in 2009-2010. Although S. pneumoniae is less common than GBS, it is associated with severe disease, a high risk of meningitis, and comparable case fatality. Because both infections have a particularly high incidence in the first week of life, future studies should focus on risk factors and strategies to prevent mother-to-infant transmission. Early infant immunization, even if initiated at birth, is likely to have limited impact on IPD in this age group, so vaccination in pregnancy may be a more promising strategy. In the meantime, continued surveillance is essential to monitor trends and changes in antibiotic resistance.
Notes
